 AIM ImmunoTech Inc said it has submitted a provisional patent application for Ampligen as a potential early-onset intranasal therapy. This therapeutic use is designed to enhance and expand infection-induced immunity, epitope spreading, cross-reactivity and cross-protection in patients exposed to a wide range of RNA respiratory viruses, such as influenza, Rhinoviruses and SARS-CoV-2, which causes the coronavirus COVID-19. 